660 related articles for article (PubMed ID: 35233549)
21. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
23. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
24. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
[TBL] [Abstract][Full Text] [Related]
25. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
26. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
[TBL] [Abstract][Full Text] [Related]
27. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
Routhu NK; Cheedarla N; Gangadhara S; Bollimpelli VS; Boddapati AK; Shiferaw A; Rahman SA; Sahoo A; Edara VV; Lai L; Floyd K; Wang S; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Upadhyay AA; Pellegrini K; Montefiori D; Shi PY; Menachery VD; Alter G; Vanderford TH; Bosinger SE; Suthar MS; Amara RR
Immunity; 2021 Mar; 54(3):542-556.e9. PubMed ID: 33631118
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
[TBL] [Abstract][Full Text] [Related]
29. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
30. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
Front Immunol; 2021; 12():729189. PubMed ID: 34603303
[TBL] [Abstract][Full Text] [Related]
31. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
32. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
33. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose.
Rossi AH; Ojeda DS; Varese A; Sanchez L; Gonzalez Lopez Ledesma MM; Mazzitelli I; Alvarez Juliá A; Oviedo Rouco S; Pallarés HM; Costa Navarro GS; Rasetto NB; Garcia CI; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Sosa S; Bianchimano L; Rios AS; Treffinger Cienfuegos MS; Caramelo JJ; Longueira Y; Laufer N; Alvarez DE; Carradori J; Pedrozza D; Rima A; Echegoyen C; Ercole R; Gelpi P; Marchetti S; Zubieta M; Docena G; Kreplak N; Yanovsky M; Geffner J; Pifano M; Gamarnik AV
Cell Rep Med; 2021 Aug; 2(8):100359. PubMed ID: 34308389
[TBL] [Abstract][Full Text] [Related]
34. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.
Sun S; Cai Y; Song TZ; Pu Y; Cheng L; Xu H; Sun J; Meng C; Lin Y; Huang H; Zhao F; Zhang S; Gao Y; Han JB; Feng XL; Yu DD; Zhu Y; Gao P; Tang H; Zhao J; Zhang Z; Yang J; Hu Z; Fu YX; Zheng YT; Peng H
Cell Res; 2021 Sep; 31(9):1011-1023. PubMed ID: 34267349
[TBL] [Abstract][Full Text] [Related]
35. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization.
Chiba S; Frey SJ; Halfmann PJ; Kuroda M; Maemura T; Yang JE; Wright ER; Kawaoka Y; Kane RS
Commun Biol; 2021 May; 4(1):597. PubMed ID: 34011948
[TBL] [Abstract][Full Text] [Related]
36. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
Roozendaal R; Solforosi L; Stieh DJ; Serroyen J; Straetemans R; Dari A; Boulton M; Wegmann F; Rosendahl Huber SK; van der Lubbe JEM; Hendriks J; Le Gars M; Dekking L; Czapska-Casey DN; Guimera N; Janssen S; Tete S; Chandrashekar A; Mercado NB; Yu J; Koudstaal W; Perez-Ruixo JJ; Sadoff J; Barouch DH; Schuitemaker H; Zahn R
Nat Commun; 2021 Oct; 12(1):5877. PubMed ID: 34620860
[TBL] [Abstract][Full Text] [Related]
38. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
[TBL] [Abstract][Full Text] [Related]
39. Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.
Fan S; Xiao K; Li D; Zhao H; Zhang J; Yu L; Chang P; Zhu S; Xu X; Liao Y; Ji T; Jiang G; Yan D; Zeng F; Duan S; Xia B; Wang L; Yang F; He Z; Song Y; Cui P; Li X; Zhang Y; Zheng B; Zhang Y; Xu W; Li Q
Emerg Microbes Infect; 2022 Dec; 11(1):212-226. PubMed ID: 34931939
[TBL] [Abstract][Full Text] [Related]
40. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
